FTRP - FTRP STOCK NEWS

Field Trip Health Ltd. (NASDAQ: FTRP), a leading provider of psychedelic-assisted therapies in Canada, announced its application for psilocybin and MDMA-assisted therapy access through Health Canada’s Special Access Program (SAP). This follows amendments allowing physicians to request restricted drugs for serious conditions. Field Trip, with health centers in Canada, the U.S., and the Netherlands, has been instrumental in advocating these changes. While the amendments are promising, Health Canada’s approval for individual applications remains uncertain.

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced that Co-Founder and CEO Joseph del Moral and Chief Scientific Officer Dr. Nathan Bryson will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. A recording of their presentation will be available on-demand starting January 10 at 7:00 a.m. ET. Interested institutional investors can schedule meetings with management through KCSA Strategic Communications.

Field Trip is a leader in psychedelic therapy development and delivery, focusing on innovative research and therapy centers.

Field Trip Health Ltd. (NASDAQ: FTRP) has launched its Site Management Organization Services to support clinical trials for psychedelic therapies. This initiative is expected to enhance revenue by leveraging Field Trip's expertise and facilities. The company operates in seven major U.S. cities and aims to become a leading center for psychedelic-assisted psychotherapy. Stéphan Côté joins as Head of Quality, bringing over 25 years of experience to refine quality systems. This expansion aligns with Field Trip’s mission to address the global mental health crisis through innovative therapies.

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced that its management will present at the H.C. Wainwright’s 2nd Annual Psychedelics Conference and Stifel’s 2nd Annual Future of Healthcare Conference in December 2021. CEO Joseph Del Moral and CSO Dr. Nathan Bryson will present at the Psychedelics Conference on December 6, while Executive Chairman Ronan Levy and Dr. Bryson will present at the Healthcare Conference on December 8. Presentations will be available on-demand, and one-on-one meetings with management can be scheduled through KCSA Strategic Communications.

Field Trip Health announced the advancement of its psychedelic compound FT-104 targeting Treatment-Resistant Depression and Postpartum Depression. The company initiated a new research pipeline, FT-200 Group, focusing on psychedelics with reduced cardiovascular risks. As of September 30, 2021, Field Trip reported $88 million in unrestricted cash. Patient services revenue surged 860% to $907,816 year-over-year. However, the company incurred a net loss of $13 million, largely due to increased operating costs. Field Trip's shares now trade on NASDAQ under symbol FTRP.

Field Trip Health Ltd. (FTRP) will participate in key healthcare conferences in November 2021. Ronan Levy, Co-founder and Executive Chairman, will attend the Microdose Wonderland: Miami Conference on November 8-9, and present at the Stifel 2021 Virtual Healthcare Conference on November 17 at 8:00 AM ET. Additionally, Field Trip's management will present at the Jefferies London Healthcare Conference on November 18-19, with a webcast available for attendees. One-on-one meetings can be scheduled with the management team during the conferences.

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced its plans to release fiscal Q2 financial results for the period ending September 30, 2021, on November 15, 2021. A conference call will follow on November 16 at 8:30 am ET to discuss results. Field Trip is a leader in psychedelic therapy, focused on developing new psychedelic molecules and establishing therapy centers across North America and Europe. The company aims to provide evidence-based healing solutions.

Field Trip Health Ltd. (NASDAQ: FTRP) has announced the opening of three new clinics in Seattle, Fredericton, and Vancouver, expanding its footprint as a global leader in psychedelic therapies. This growth comes amid rising demand for mental health treatments, particularly for conditions like anxiety and depression. Notably, clients have reported significant improvements in depression symptoms, with average scores decreasing from 17 to 6 on the PHQ9 scale. Field Trip emphasizes its commitment to providing innovative, evidence-based therapies designed to foster healing and personal growth.

Field Trip Health Ltd. (TSX: FTRP; Nasdaq: FTRP) announced that CEO Joseph del Moral will present at the KCSA Psychedelics Investor Conference on October 13, 2021, at 12:30pm ET. This virtual conference streamlines discussions about psychedelic therapies, an area where Field Trip is a recognized leader. The company is advancing the development of psychedelic molecules and expanding therapy centers across North America and Europe. Interested parties can register for the conference online.